Lumateperone
id:
lumateperone-179-1831221
title:
Lumateperone
text:
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy. It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, and became available in February 2020. It has sinc
brand slug:
wiki
category slug:
encyclopedia
description:
Atypical antipsychotic
original url:
https://en.wikipedia.org/wiki/Lumateperone
date created:
2015-05-19T12:55:34Z
date modified:
2024-09-04T21:06:05Z
main entity:
{"identifier":"Q21098913","url":"https://www.wikidata.org/entity/Q21098913"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/24/ITI-007.svg","width":512,"height":191}
fields total:
13
integrity:
16